Stimulation of erythropoiesis by in vivo gene therapy: physiologic consequences of transfer of the human erythropoietin gene to experimental animals using an adenovirus vector. Academic Article uri icon

Overview

MeSH

  • Adenoviridae
  • Animals
  • Anoxia
  • Base Sequence
  • Genetic Vectors
  • Humans
  • Molecular Sequence Data
  • Promoter Regions, Genetic
  • Sigmodontinae

MeSH Major

  • Erythropoiesis
  • Erythropoietin
  • Genetic Therapy

abstract

  • Erythropoietin (Epo), a 30.4-kD glycoprotein, is the principal regulator of erythropoiesis. To evaluate the concept that in vivo gene transfer might be used as an alternative to recombinant human Epo (rhEpo) in applications requiring a 1- to 3-week stimulation of erythropoiesis, the replication-deficient recombinant adenovirus AdMLP.Epo was constructed by deleting the majority of E1 from adenovirus type 5, and replacing E1 with an expression cassette containing the adenovirus type 5 major late promoter (MLP) and the human Epo gene, including the 3' cis-acting hypoxia response element. In vitro studies showed that infection of the human hepatocyte cell line Hep3B with AdMLP.Epo resulted in a 15-fold increase in Epo production in 24 hours that was enhanced to 116-fold in the presence of a hypoxic stimulus. One-time in vivo administration of AdMLP.Epo (7 x 10(9) plaque-forming units/kg) to the peritoneum of cotton rats caused a marked increase in red blood cell production, with a 2.6-fold increase in bone marrow erythroid precursors by day 4, and sevenfold increase in reticulocyte count by day 7. The hematocrit increased gradually, with a maximum of 64% +/- 4% at day 14 (compared with an untreated baseline of 46% +/- 2%), and a level of 55% +/- 1% at day 24. Furthermore, one-time subcutaneous administration of AdMLP.Epo caused an increase in hematocrit that peaked at 14 days (57% +/- 2%) and was still elevated at day 42. Hematocrit level in animals receiving subcutaneous administration of AdMLP.Epo sustained a long-term increase compared with animals receiving intraperitoneal administration. In the context of these observations, gene therapy with a single administration of an adenovirus vector containing the human EPO gene may provide a means of significantly augmenting the circulating red blood cell mass over the 1- to 3-week period necessary for many clinical applications.

publication date

  • November 1, 1994

has subject area

  • Adenoviridae
  • Animals
  • Anoxia
  • Base Sequence
  • Erythropoiesis
  • Erythropoietin
  • Genetic Therapy
  • Genetic Vectors
  • Humans
  • Molecular Sequence Data
  • Promoter Regions, Genetic
  • Sigmodontinae

Research

keywords

  • Journal Article

Identity

Language

  • eng

PubMed ID

  • 7949166

Additional Document Info

start page

  • 2946

end page

  • 2953

volume

  • 84

number

  • 9